OA Dr. Christoph Suppan, Universitätsklinik für Innere Medizin, Graz, fasst die neuen Daten bei frühem Brustkrebs zusammen und erklärt, wie Onkologen zu einer höheren Therapieadhärenz beitragen können.

Abstracts

LBA14_PR – The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer
comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.
F. Perrone

185O_PR – Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO
cohort
B. Pistilli

186O – Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
M.V. Dieci

LBA12_PR – PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results
C. Hulme

Quelle: ESMO 2018

Mammakarzinom